CS3 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING COMPARED TO STANDARD BLOOD PRESSURE CONTROL ALONE FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA IN SPANISH, SWEDISH AND SWISS SETTINGS
Nov 1, 2004, 00:00
10.1016/S1098-3015(10)65692-6
https://www.valueinhealthjournal.com/article/S1098-3015(10)65692-6/fulltext
Title :
CS3 IRBESARTAN IS PROJECTED TO BE COST AND LIFE SAVING COMPARED TO STANDARD BLOOD PRESSURE CONTROL ALONE FOR TREATMENT OF PATIENTS WITH TYPE 2 DIABETES, HYPERTENSION, AND MICROALBUMINURIA IN SPANISH, SWEDISH AND SWISS SETTINGS
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65692-6&doi=10.1016/S1098-3015(10)65692-6
First page :
Section Title :
Open access? :
No
Section Order :
59